Francois Cedric's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Mar 5, 2024
- Accession no.
- 0001127602-24-008505
- Filed
- Mar 5, 2024
- Trade date
- Mar 1, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 2 derivative transactions. Open-market sales total $16.0M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Francois CedricCIK 0001658080 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2024 | Common Stock | MOption exerciseAcquired | +50,000 | $3.76 | +$188,000 | 363,662 | Direct | |
| Mar 1, 2024 | Common Stock | MOption exerciseAcquired | +200,000 | $4.31 | +$862,000 | 563,662 | Direct | |
| Mar 1, 2024 | Common Stock | SSaleDisposed | −28,868 | $62.21 | −$1,795,878.28 | 534,794 | Direct | |
| Mar 1, 2024 | Common Stock | SSaleDisposed | −41,704 | $62.96 | −$2,625,683.84 | 493,090 | Direct | |
| Mar 1, 2024 | Common Stock | SSaleDisposed | −62,503 | $64.26 | −$4,016,442.78 | 430,587 | Direct | |
| Mar 1, 2024 | Common Stock | SSaleDisposed | −116,512 | $64.92 | −$7,563,959.04 | 314,075 | Direct | |
| Mar 1, 2024 | Common Stock | SSaleDisposed | −413 | $65.68 | −$27,125.84 | 313,662 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2024 | Common Stock | MOption exerciseDisposed | −50,000 | $0.00 | $0 | 8,840 | Direct | |
| Mar 1, 2024 | Common Stock | MOption exerciseDisposed | −200,000 | $0.00 | $0 | 175,538 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.